Cognition Therapeutics Announces Participation in Upcoming September Conferences
30 Agosto 2023 - 9:00AM
Cognition Therapeutics, Inc. (Nasdaq:
CGTX), a clinical-stage neuroscience company
developing drugs that treat neurodegenerative disorders by
regulating cellular damage response pathways (the “Company” or
“Cognition”), announced that Lisa Ricciardi, Chief Executive
Officer, will deliver a company presentation at the H.C. Wainwright
Annual Global Investment Conference and participating on a panel at
the Cantor Fitzgerald Global Healthcare Conference in September
2023. In addition, she will be moderating a panel on pipeline
prioritization strategies at the Longwood Healthcare Leaders Fall
Conference, a brainstorming forum of pharmaceutical, healthcare and
investment leaders focused on accelerating the translation of
discoveries into medicines.
Presentation Details: H.C. Wainwright Annual
Global Investment Conference
Dates: September 11-13,
2023Presentation Day/Time: September 13 at 4:00 pmLocation: Kennedy
II, Lotte New York Palace, New YorkLive webcast will be available
on the events and presentations section of Cognition’s IR site
during the event
Longwood Healthcare Leaders Fall Conference
Dates: September 18-19,
2023Presentation Day/Time: September 19 at 4:10pmLocation: Harvard
Medical School, Boston
Cantor Fitzgerald Global Healthcare Conference
Dates: September 26-28,
2023Presentation Day/Time: September 26 at 9:20 amLocation:
Intercontinental Barclay Hotel, New YorkLive webcast will be
available on the events and presentations section of Cognition’s IR
site during the event
About Cognition Therapeutics:Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical
programs in Alzheimer’s disease, dementia with Lewy bodies
(DLB) and dry age-related macular degeneration (dry AMD). We
believe CT1812 and our pipeline of σ-2 receptor modulators can
regulate pathways that are impaired in these diseases. We believe
that targeting the σ-2 receptor with CT1812 represents a mechanism
functionally distinct from other current approaches in clinical
development for the treatment of degenerative diseases. More about
Cognition Therapeutics and its pipeline can be found
at https://cogrx.com/.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, are forward-looking statements. These
statements, including statements relating to the timing and
expected results of our clinical trials, and cash
runway, involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied
by the forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition; our ability to secure new (and retain existing)
grant funding; our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
uncertainties inherent in the results of preliminary data and
pre-clinical studies being predictive of the results of clinical
trials; the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors, including ongoing economic uncertainty; our
estimates of expenses and profitability; the evolution of the
markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our
ability to defend our intellectual property; the impact of the
ongoing COVID-19 pandemic on our business, supply chain and labor
force; and the risks and uncertainties described in the “Risk
Factors” section of our annual and quarterly reports filed
the Securities Exchange Commission. These risks are not
exhaustive and we face both known and unknown risks. You should not
rely on these forward-looking statements as predictions of future
events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur, and actual
results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in a dynamic
industry and economy. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict
all risk factors and uncertainties that we may face. Except as
required by applicable law, we do not plan to publicly update or
revise any forward-looking statements contained herein, whether as
a result of any new information, future events, changed
circumstances or otherwise.
Contact Information: Cognition Therapeutics, Inc.
info@cogrx.com
Casey McDonald (media) Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
Daniel Kontoh-Boateng (investors) Tiberend Strategic Advisors,
Inc. dboateng@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024